Gossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed as Buy by Chardan Capital

Posted by Brenda Bartman on Oct 26th, 2026

Gossamer Bio (NASDAQ:GOSS – Get Free Report)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a note issued to investors on Monday, Benzinga reports.

A number of other research analysts have also issued reports on the stock. Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a research report on Tuesday, July 28th. Finally, Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Gossamer Bio currently has an average rating of “Hold” and a consensus target price of $256.00.

Read Our Latest Analysis on GOSS

Gossamer Bio Stock Performance

Shares of GOSS stock traded down $0.56 on Monday, hitting $9.04. The company’s stock had a trading volume of 93,151 shares, compared to its average volume of 240,373. The stock’s 50 day moving average is $11.48 and its 200-day moving average is $16.16. Gossamer Bio has a fifty-two week low of $8.29 and a fifty-two week high of $309.60. The company has a market capitalization of $55.25 million, a PE ratio of -0.16 and a beta of 2.21.

Institutional Trading of Gossamer Bio

Large investors have recently made changes to their positions in the company. Kalehua Capital Management LLC acquired a new stake in shares of Gossamer Bio during the 1st quarter worth approximately $3,363,000. GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio during the 2nd quarter worth approximately $2,467,000. ARCH Venture Management LLC acquired a new stake in shares of Gossamer Bio during the 2nd quarter worth approximately $1,326,004. BlackRock Inc. acquired a new stake in shares of Gossamer Bio during the 2nd quarter worth approximately $1,262,000. Finally, Bank of America Corp DE boosted its position in shares of Gossamer Bio by 66.5% during the 1st quarter. Bank of America Corp DE now owns 3,173,725 shares of the company’s stock worth $1,041,000 after acquiring an additional 1,267,056 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.